suppurativa disease 13/10/2015 | 17:410 commentsSide of the conference Started Amal AllamIt announced the company “Opfy” of drugs, the global leader in the development of drugs and medical drugs, new scientific results of the effectiveness of the drug “Hummera” (Adalimumab) for the treatment of hidradenitis suppurativa disease. This comes during the annual global conference of the European Academy of Dermatology and Venereal (EADV) held this year in Copenhagen , Denmark, during the period from 7 to 11 Oct., where the Opfy company Gold Sponsors of the conference. she said , “Opfy” in a statement, that the company launched during the conference sessions , the 26 summary medically for new treatment “Hummera” (Adalimumab) processor for hidradenitis suppurativa hidradenitis suppurativa noting that during the sessions of the conference offered the most important scientific discoveries of the disease psoriasis and psoriatic arthritis. The company said it has expanded in the field of data and medical research on hidradenitis suppurativa HS disease, which proved that the skin disease is an inflammatory painful and chronic usually affects 1 % of the population (about one million Egyptian patients), and there are no reasons certain of his appearance, the longer the treatment, diagnosis is difficult, due to the passing phases of activity and inactivity continues, so prefer to follow – up with leather and gonad an experienced doctor, the similarity of the disease in several other diseases. Dr. Mherh Hamdi al- Sayyid, a professor dermatologists, said: “disease causes a number of complications including scars and changes of skin, and cause pain during movement, especially if it happened in the armpits and thighs, as the disease rheumatoid arthritis and Crohn ‘s disease is associated, if hit inflammation of the sweat glands adjacent to the groin area and anal” . it continued: “Smoking and obesity have a negative role on the disease and stop smoking and lose weight have an active role in treatment, a significant effect on the psychological condition of the patient.” she added that recently was approved drug “Humira” for the treatment of inflammation of the sweat glands disease purulent moderate to severe, by multiple health authorities , including the European food and medicine body, body food and drug Administration (FDA) and the Health Authority in Bosnia. She noted that before the registration treat Alhummera, there was no treatment for hidradenitis suppurativa officially registered for this disease, so it is the hope of treatment new patients in restoring their lives to normal, as the patient in this case is suffering from pain and depression and isolation from the community. the studies conducted on the drug Humira, one of the most comprehensive available biological studies, characterized the experience up to 18 years in Alakleniech experiments in immunology diseases , such as rheumatoid arthritis, which causes the erosion of joints, stiff and serious pain in the parties. The company reported that the EU issued instructions on the safe use of medication Hummera including: You should not use Humira with patients who suffer from active tuberculosis or acute other inflammatory disease, patients suffering from the failure of the heart muscle. announced a new drug to treat inflammation of the sweat glands disease purulent every disease drug company “Opfy” of drugs, the global leader in the development of drugs and medical drugs, announced a new scientific results of the effectiveness of the drug “Hummera” (Adalimumab) for the treatment of inflammatory disease purulent sweat glands.